Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODIS: Raltegravir Once Daily vs Twice Daily in HIV
NCT00941083Phase 4Unknown
- Start
- Jan 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoint: Proportion of patients with plasma HIV-RNA < 50 copies/ml at 24 weeks. Status: unknown.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00941083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941083.